NCT03471286View on ClinicalTrials.gov

A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies

PHASE1TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

June 6, 2019

Primary Completion Date

July 30, 2021

Study Completion Date

July 30, 2021

Conditions

Solid Tumor

Interventions

DRUG

Epacadostat

Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER